The U.S. Environmental Protection Agency (EPA) and the Department of Health and Human Services (HHS) have announced a major new initiative to monitor microplastics and pharmaceutical residues in the drinking water of the U.S. It marks an important step to understand their potential health risks and shape the future regulatory policy. The move reflects growing public concern, mounting scientific evidence, and sustained pressure from state leaders and environmental advocates.
Under this initiative, microplastics and pharmaceuticals will be added to the EPA’s sixth Contaminant Candidate List (CCL). This list includes substances that are not currently regulated but are known or anticipated to occur in public water systems. Inclusion means these contaminants will undergo nationwide monitoring, research funding, and risk assessment under the Safe Drinking Water Act. While this does not immediately impose regulatory limits, it is widely seen as a precursor to potential future standards if sufficient evidence demonstrates harm to human health.
Health Secretary Robert F. Kennedy Jr. highlighted the importance of data-driven policymaking and said that effective regulation depends on accurate measurement and understanding. EPA Administrator Lee Zeldin confirmed this view, describing the decision as a long-overdue response to the public concern about the contaminants in the drinking water. Both officials framed the initiative as part of President Donald Trump’s broader “Make America Healthy Again” agenda, which prioritizes environmental health alongside other policy shifts.
The decision follows a coordinated push from policymakers and advocacy groups. In late 2025, seven U.S. governors, including leaders from New Jersey and Michigan, joined more than 175 environmental and public health organizations in urging the EPA to formally include microplastics in its monitoring framework. Their petition underscored the urgency of addressing contaminants increasingly detected in both ecosystems and human bodies.
Microplastics, defined as tiny plastic particles <5 mm in size, have been found in a wide range of environments from ocean depths and Arctic ice to human blood, lungs, and even placental tissue. Some studies suggest potential links between microplastic exposure and serious health outcomes, which include cancer and reproductive harm. However, the science remains inconclusive, with ongoing debate about the extent and mechanisms of these risks.
Environmental advocates have appreciated the move by the EPA as an important first step. Judith Enck, president of Beyond Plastics and a former EPA regional administrator, described the decision as progress while highlighting the need for stronger regulatory action in the future. Industry groups, however, have urged caution. Representatives from the American Chemistry Council, which represents plastic manufacturers, have stated their support for monitoring efforts but maintain that existing research does not definitively establish harm from microplastic exposure.
The inclusion of pharmaceuticals in monitoring efforts highlights growing concern. Pharmaceutical compounds can enter water systems by improper disposal of medications and through human excretion. Trace amounts of drugs, which include antibiotics, hormones, and antidepressants, have been detected in water supplies. It raises questions about long-term exposure and ecological impacts. The EPA plans to release human health benchmarks for 374 pharmaceutical compounds, which provide a scientific basis to evaluate their potential risks to address this.
This initiative also highlights broader tensions in environmental policy. While Robert F. Kennedy Jr. has long advocated for reducing plastic pollution, which includes limiting production, the current administration has previously resisted international efforts to cap plastic manufacturing under a proposed United Nations treaty. This contrast highlights the complexity of balancing environmental protection, industrial interests, and global policy commitments.
Overall, the decision to monitor microplastics and pharmaceuticals represents a foundational step to address emerging contaminants in the drinking water. By prioritizing research and data collection, federal agencies aim to close critical knowledge gaps and build the scientific consensus needed for future regulation.
Reference: Reuters. Water Watch: US Steps Up Monitoring for Microplastics and Pharmaceuticals. Published April 2, 2026. Accessed April 3, 2026. US agencies to monitor drinking water for microplastics, pharmaceuticals
